TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07901751: Phase 2/3, Double-masked, Randomized, Sham-controlled, Single Dose Study to Evaluate the Efficacy of a Single Intravitreal Injection of RTx-015 in Participants With Retinitis Pigmentosa (PERCEPT)

Sponsor: Ray Therapeutics, Inc. · Phase: PHASE2/PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 60 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$3,280,824

Rescue Site Savings

+$2,146,712

Unlock Full NCT07901751 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07901751 Rescue Dossier →